UA126848C2 - Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva) - Google Patents
Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva) Download PDFInfo
- Publication number
- UA126848C2 UA126848C2 UAA201702987A UAA201702987A UA126848C2 UA 126848 C2 UA126848 C2 UA 126848C2 UA A201702987 A UAA201702987 A UA A201702987A UA A201702987 A UAA201702987 A UA A201702987A UA 126848 C2 UA126848 C2 UA 126848C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mma
- filovirus
- recombinant
- encodes
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045538P | 2014-09-03 | 2014-09-03 | |
| US201462055154P | 2014-09-25 | 2014-09-25 | |
| PCT/EP2015/070161 WO2016034678A2 (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126848C2 true UA126848C2 (uk) | 2023-02-15 |
Family
ID=54145734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201702987A UA126848C2 (uk) | 2014-09-03 | 2015-09-03 | Філовірусна вакцина на основі рекомбінантного модифікованого вірусу вісповакцини анкара (mva) |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10576141B2 (enExample) |
| EP (1) | EP3188752A2 (enExample) |
| JP (2) | JP6823586B2 (enExample) |
| KR (2) | KR102812180B1 (enExample) |
| CN (2) | CN112972668A (enExample) |
| AU (2) | AU2015310909B2 (enExample) |
| CA (1) | CA2959105C (enExample) |
| IL (2) | IL250552B (enExample) |
| MX (1) | MX2017002791A (enExample) |
| MY (1) | MY193417A (enExample) |
| SG (2) | SG10201901735XA (enExample) |
| UA (1) | UA126848C2 (enExample) |
| WO (1) | WO2016034678A2 (enExample) |
| ZA (1) | ZA201701077B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| EP3421046A1 (en) | 2014-11-04 | 2019-01-02 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv16 vaccines |
| CN106999196B (zh) * | 2014-11-26 | 2020-07-28 | 尼尔拉维有限公司 | 从血管除去阻塞性血栓的取血栓装置 |
| US11701418B2 (en) * | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| US20190030157A1 (en) | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3872180A1 (en) * | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| WO2018185732A1 (en) | 2017-04-06 | 2018-10-11 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| CA3062549A1 (en) * | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| US20200171141A1 (en) * | 2017-07-18 | 2020-06-04 | Geovax, Inc. | Compositions and Methods for Generating an Immune Response to LASV |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| GB201716181D0 (en) * | 2017-10-04 | 2017-11-15 | Univ Cape Town | Recombinant mva with modified hiv-1 env |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| EP3856239A2 (en) * | 2018-09-28 | 2021-08-04 | The Chancellor, Masters and Scholars of the University of Cambridge | Vaccines and methods |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| JP7712284B2 (ja) | 2020-03-12 | 2025-07-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルスの安定性を改善する組成物 |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| MX2023014564A (es) * | 2021-06-17 | 2024-03-05 | Elixirgen Therapeutics Inc | Vacunas de arn autorreplicante, controlables por temperatura, para enfermedades virales. |
| CN115819616B (zh) * | 2021-07-28 | 2025-04-11 | 江苏瑞科生物技术股份有限公司 | 一种基因重组vzv融合蛋白及其制备方法和应用 |
| WO2024188801A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
| AU2024236322A1 (en) | 2023-03-10 | 2025-08-21 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| IL322961A (en) | 2023-03-10 | 2025-10-01 | Bavarian Nordic As | Production of smallpox viruses from cell cultures |
| WO2026006679A1 (en) * | 2024-06-28 | 2026-01-02 | The Regents Of The University Of California | Retroviral vectors |
| WO2026087525A1 (en) * | 2024-10-21 | 2026-04-30 | Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern | A deliverable cytosolic gene expression system based on poxviral rna polymerase and dna templates |
| CN120795167B (zh) * | 2025-04-15 | 2026-05-08 | 佰芮慷(广州)细胞医药科技有限公司 | 一种靶向人eb病毒的嵌合抗原受体car、car-nk细胞及用途 |
| CN120843742A (zh) * | 2025-09-09 | 2025-10-28 | 军事科学院军事医学研究院军事兽医研究所 | 一种泛哺乳动物丝状病毒检测用引物组及其检测试剂盒和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2462455C (en) * | 2001-10-01 | 2012-07-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| EP1586331B1 (en) * | 2001-10-01 | 2008-05-28 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| WO2010048615A2 (en) * | 2008-10-24 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention | Human ebola virus species and compositions and methods thereof |
| EP2352834B1 (en) | 2008-11-21 | 2016-12-21 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| EP2473525A4 (en) * | 2009-09-02 | 2013-08-21 | Us Army | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS |
| WO2011130627A2 (en) * | 2010-04-16 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| KR20220012403A (ko) | 2012-04-12 | 2022-02-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| EP2892549A1 (en) * | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 CA CA2959105A patent/CA2959105C/en active Active
- 2015-09-03 MX MX2017002791A patent/MX2017002791A/es unknown
- 2015-09-03 UA UAA201702987A patent/UA126848C2/uk unknown
- 2015-09-03 MY MYPI2017700483A patent/MY193417A/en unknown
- 2015-09-03 CN CN202110238900.XA patent/CN112972668A/zh active Pending
- 2015-09-03 AU AU2015310909A patent/AU2015310909B2/en active Active
- 2015-09-03 CN CN201580047328.1A patent/CN106999565B/zh active Active
- 2015-09-03 JP JP2017510880A patent/JP6823586B2/ja active Active
- 2015-09-03 KR KR1020237030452A patent/KR102812180B1/ko active Active
- 2015-09-03 WO PCT/EP2015/070161 patent/WO2016034678A2/en not_active Ceased
- 2015-09-03 SG SG10201901735XA patent/SG10201901735XA/en unknown
- 2015-09-03 EP EP15763853.7A patent/EP3188752A2/en active Pending
- 2015-09-03 KR KR1020177006091A patent/KR102736868B1/ko active Active
- 2015-09-03 SG SG11201701506PA patent/SG11201701506PA/en unknown
- 2015-09-03 US US15/508,851 patent/US10576141B2/en active Active
-
2017
- 2017-02-12 IL IL250552A patent/IL250552B/en unknown
- 2017-02-13 ZA ZA2017/01077A patent/ZA201701077B/en unknown
-
2020
- 2020-02-27 US US16/802,805 patent/US11338030B2/en active Active
-
2021
- 2021-01-06 JP JP2021000975A patent/JP7113924B2/ja active Active
- 2021-07-28 AU AU2021209228A patent/AU2021209228A1/en not_active Abandoned
-
2022
- 2022-01-23 IL IL290052A patent/IL290052A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン | |
| Zhao et al. | Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges | |
| Qin et al. | Identification of novel T-cell epitopes on infectious bronchitis virus N protein and development of a multi-epitope vaccine | |
| US20240374710A1 (en) | Vaccine Compositions For Preventing Coronavirus Disease | |
| ES2629860T3 (es) | Vectores virales recombinantes | |
| ES2535310T3 (es) | Atenuación sinérgica del virus de la estomatitis vesicular, vectores del mismo y composiciones inmunogénicas del mismo | |
| JP6523955B2 (ja) | 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン | |
| Kerstetter et al. | Adenoviral vectors as vaccines for emerging avian influenza viruses | |
| Hu et al. | Generation and evaluation of a recombinant Newcastle disease virus expressing the glycoprotein (G) of avian metapneumovirus subgroup C as a bivalent vaccine in turkeys | |
| UA126860C2 (uk) | Цитомегаловірусні вектори, що вибирають t-клітини, обмежені по молекулах головного комплексу гістосумісності e | |
| EA002390B1 (ru) | Полиоболочечная вирусная вакцина против вируса иммунного дефицита человека (вич), способ генерации гуморального и/или клеточного иммунного ответа у млекопитающих на вич и бифункциональная плазмида | |
| CN104962581B (zh) | 一种表达非洲猪瘟病毒p72蛋白的重组病毒疫苗株 | |
| CN113453710A (zh) | 疫苗和方法 | |
| UA123385C2 (uk) | Рекомбінантний модифікований вірус вісповакцини анкара (mva) та спосіб лікування або попередження інфекцій вірусу rsv | |
| Boudewijns et al. | MVA-CoV2-S vaccine candidate neutralizes distinct variants of concern and protects against SARS-CoV-2 infection in hamsters | |
| US20190117758A1 (en) | Compositions and Methods for Generating an Immune Response to a Hemorrhagic Fever Virus | |
| US20140377295A1 (en) | Influenza vaccines containing modified adenovirus vectors | |
| Johnson et al. | Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice | |
| JP5884100B2 (ja) | 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有するＤＩｓ株由来組換えワクシニアウイルス | |
| Gao et al. | A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV | |
| CN107841513B (zh) | 基于M2e表位的广谱型流感疫苗 | |
| Wiegand et al. | Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector | |
| Cobela García | A novel vaccine platform for Lassa virus | |
| US20240415905A1 (en) | Medication for influenza | |
| EP4108257A1 (en) | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |